By Kang Seung-woo
BioTNS, a specialist in ultra-precision liquid biopsies, stated Tuesday that it has launched into a global blood most cancers challenge utilizing its self-developed Digital PCR platform, LQ Suite.
Formally titled “Growth and Commercialization of a Blood Most cancers Precision Analysis Platform Primarily based on Multi-omics/Digital Built-in Evaluation,” the challenge is a large-scale initiative supported by the Ministry of Commerce, Business and Vitality, involving 14 home and worldwide hospitals and the Ulsan Nationwide Institute of Science and Know-how (UNIST).
Professor Kim Dong-wook of Eulji College Hospital, who’s the general challenge coordinator, and professor Kim Hong-tae of UNIST, the chairman of the operation committee, are main this initiative.
The last word aim of the challenge is to commercialize at the very least 5 kinds of blood most cancers diagnostic kits and diagnostic tools primarily based on Digital PCR, and to ascertain a worldwide blood most cancers community.
BioTNS is planning to develop ultra-precision diagnostic kits utilizing genetic biomarkers presently owned or newly developed by the challenge group. Medical trials will likely be performed utilizing samples offered by taking part hospitals. After acquiring the required approvals, these hospitals will operate as demand shops, and BioTNS additionally plans to enter worldwide markets.
The corporate has already developed two kinds of blood most cancers diagnostic kits. Its package for persistent myeloid leukemia (CML) will start the regulatory approval course of with the U.S. Meals and Drug Administration this month and is anticipated to obtain approval early subsequent 12 months and begin supplying home hospitals. With the approval of those blood most cancers diagnostic kits, BioTNS anticipates getting into a big development section in gross sales, providing LQ Suite tools, consumables and diagnostic kits concurrently.
Launched by the corporate in 2021, the LQ Suite Digital PCR platform, primarily based on microdroplet know-how, presents sooner, extra exact and less expensive diagnostics in comparison with conventional tissue biopsies, imaging diagnostics and second-generation PCR applied sciences. This platform, offering the very best precision in current diagnostic know-how (99.99 %), marks the widespread distribution of a groundbreaking know-how able to diagnosing most cancers from only a drop of blood.
“The corporate is dedicated to persevering with the event of revolutionary most cancers diagnostics merchandise primarily based on the LQ Suite Digital PCR platform, aiming to guide the ultra-precision liquid biopsy market within the period of precision medication,” BioTNS CEO Lee Seung-il stated.